287401-40-5Relevant academic research and scientific papers
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
-
, (2017/12/15)
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
-
, (2017/12/16)
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. Formula (I).
The first syntheses of the 1-oxo-2-oxa-5-azaspiro[3.4]octane ring system found in oxazolomycin
Papillon, Julien P. N.,Taylor, Richard J. K.
, p. 1987 - 1990 (2007/10/03)
matrix presented L-Proline was utilized to prepare an optically active 1-oxo-2-oxa-5-azaspiro[3.4]octane for the first time. The synthesis of the racemic system, using a tandem aldol-lactonization reaction, is also described. Ruthenium tetroxide oxidation of these compounds afforded the corresponding spiro β-lactone γ-lactams.
